Released Sep 14, 2022, after the close
10-Q filed Sep 14, 2022, 45 days after period end · 0001654954-22-012513
Q3 2022 · 10-Q
Revenue$4.77M$4.77M −4.3% vs Q3 2021−3.9% vs Q2 2022
Net Income$288.03K$288.03K −87.3% vs Q3 2021+20.0% vs Q2 2022
EPS, diluted—
Gross Profit$1,312,314+4.6%
Operating Income$369,505+2.5%
Operating Cash Flow$1,105,853+150.3%
Free Cash Flowderived$1,103,766+154.0%
Margins · derived
Gross margin27.5%+2.3 pt vs Q3 2021
Operating margin7.7%+0.5 pt vs Q3 2021
Net margin6.0%−39.6 pt vs Q3 2021
What the release said
The release
Same quarter
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $4.77M | $4.99M | $6.28M | $4.97M |
| Net Income | $288.03K | $2.28M | $692.11K | $431.16K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR